Clinical Trials

8 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Neoplasms, Glandular and Epithelial × Clear all
NCT04774952 2025-04-15

Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

Revolution Medicines, Inc.

Phase 1 Completed
58 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Esophageal Diseases, Esophageal Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Melanoma, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Skin Neoplasms, Thoracic Neoplasms, Uterine Neoplasms, Neoplasms, Squamous Cell

NCT02164461 2024-05-20

Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer

Advaxis, Inc.

Phase 1 Completed
12 enrolled 18 charts
GynecologicThoracic

Adenocarcinoma, Carcinoma, Carcinoma, Squamous Cell, Uterine Cervical Diseases, Uterine Cervical Neoplasms, Genital Diseases, Female, Genital Neoplasms, Female, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Urogenital Neoplasms, Uterine Diseases, Uterine Neoplasms, Carcinoma, Adenosquamous, Carcinoma, Small Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma

NCT03634982 2022-09-01

Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

Revolution Medicines, Inc.

Phase 1 Unknown
133 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Esophageal Diseases, Esophageal Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Melanoma, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Noonan Syndrome, Ovarian Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Skin Neoplasms, Thoracic Neoplasms, Uterine Neoplasms, Neoplasms, Squamous Cell

NCT02897778 2022-04-28

Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors

Syndax Pharmaceuticals

Phase 1 Completed
30 enrolled
BreastGastrointestinalGenitourinaryThoracic

Breast Diseases, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Digestive System Neoplasms, Endocrine Gland Neoplasms, Kidney Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT02909452 2022-01-25

Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Syndax Pharmaceuticals

Phase 1 Completed
30 enrolled
BreastGastrointestinalGenitourinaryThoracic

Breast Diseases, Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Digestive System Neoplasms, Endocrine Gland Neoplasms, Kidney Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Respiratory Tract Neoplasms, Thoracic Neoplasms